Online inquiry

IVTScrip™ mRNA-Anti-TNFRSF10B, AMG 655(Cap 0, 2-Thio-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ2667MR)

This product GTTS-WQ2667MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets TNFRSF10B gene. The antibody can be applied in Non-small Cell Lung Cancer (NSCLC) research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_003842.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 8795
UniProt ID O14763
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TNFRSF10B, AMG 655(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) (GTTS-WQ2667MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ11199MR IVTScrip™ mRNA-Anti-TNFRSF18, MEDI-1873(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA MEDI-1873
GTTS-WQ12392MR IVTScrip™ mRNA-Anti-SAA1, NEOD-001(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA NEOD-001
GTTS-WQ1029MR IVTScrip™ mRNA-Anti-MET, ABBV-399(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA ABBV-399
GTTS-WQ8382MR IVTScrip™ mRNA-Anti-TACSTD2, aTROP2S7(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA aTROP2S7
GTTS-WQ9682MR IVTScrip™ mRNA-Anti-CD19&CD3E, JNJ-64052781(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA JNJ-64052781
GTTS-WQ7209MR IVTScrip™ mRNA-Anti-CD19, FMC63 scFv-8A-F9Z CAR(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA FMC63 scFv-8A-F9Z CAR
GTTS-WQ10174MR IVTScrip™ mRNA-Anti-SELP, LC1004-002(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA LC1004-002
GTTS-WQ8800MR IVTScrip™ mRNA-Anti-PDCD1, IBI-308(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA IBI-308
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW